Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Therapeutics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2015.11.008PMID 26687552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India

  2016cited by this paper
• Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

  2016cited by this paper
• Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants

  2015cited by this paper
• Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, and assessment of dose proportionality in healthy participants

  2015cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.

  2015cited by this paper
• Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

  2015cited by this paper
• Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.

  2015cited by this paper
• PO422 EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM INDIA

  2014cited by this paper
• Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

  2014cited by this paper
• Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans

  2014cited by this paper
• Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

  2013cited by this paper
• Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

  2013cited by this paper
• Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

  2013cited by this paper
• Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

  2013cited by this paper
• Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

  2013cited by this paper
• Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion

  2013cited by this paper
• Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

  2012cited by this paper
• Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

  2012cited by this paper
• Therapy in the Early Stage: Incretins

  2011cited by this paper
• Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

  2011cited by this paper
• IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

  2011cited by this paper
• IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.

  2011cited by this paper
• Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

  2010cited by this paper
• Sodium-Glucose Co-Transport Inhibitors

  2010cited by this paper
• The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

  2008cited by this paper
• Diabetes Treatment, Part 2: Oral Agents for Glycemic Management

  2007cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Predictability of the effects of race or ethnicity on pharmacokinetics of drugs.

  2000cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper

• Clinical pharmacokinetics on canagliflozin: a systematic review of in-vitro and in-vivo studies

  2025influential citation
• Inibitori del cotrasportatore sodio-glucosio di tipo 2 in pazienti sottoposti a trapianto renale

  2023cites this paper
• Model‐based meta‐analysis of ethnic differences and their variabilities in clearance of oral drugs classified by clearance mechanism

  2023cites this paper
• Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?

  2022cites this paper
• Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection

  2022cites this paper
• Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds

  2022cites this paper
• Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients

  2021cites this paper
• A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

  2021cites this paper
• Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions.

  2020cites this paper
• Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

  2020cites this paper
• Ion-pair solid phase extraction for the simultaneous separation and quantitation of metformin and canagliflozin in human plasma by LC-MS/MS

  2018cites this paper
• A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

  2017cites this paper
• Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

  2015cites this paper